>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • MRVL -3.9%
Select EU financial related names showing weakness:
  • LYG -3%, BCS -1.1%, DB -1.1%
Other news:
  • TNXP -51.8% (reports topline results from phase 3 Affirm study of TNX-102 SL in fibromyalgia, provides corporate update)
  • KPTI -8.2% (reports top-line results from its Phase 2b STORM study)
  • VIP -6.9% (accepted the resignation of Mikhail Slobodin, CEO of VimpelCom Russia, with immediate effect)
  • ARWR -2.1% (files for 7,627,119 share Common Stock offering by the selling security holders)
  • SHPG -0.5% (files for debt securities shelf offering)
Analyst comments:
  • CNC -1.2% (downgraded to Mkt Perform at Leerink Partners)
  • DG -0.7% (coverage assumed / downgraded to Neutral from Buy at Goldman)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance: NSSC +10.5%, MDXG +2%, MEIP +1.1%, ALR +0.9%

M&A news: CPHD +52.1% (to be acquired by Danaher (DHR) for $53.00/share in cash for ~$4 bln enterprise value), BHP +1.1% ( Woodside (WOPEY) agrees to acquire half of BHP Billiton's Scarborough area assets), MON +0.5% (Bayer (BAYRY) confirms in advanced negotiations with Monsanto concerning proposed transaction)

Select metals/mining stocks trading higher: AUY +4.4%, AG +3.8%, MT +3%, SLW +2.8%, ABX +2.7%, GG +2.5%, NEM+1.9%, GDX +1.8%

Select oil/gas related names showing strength: CHK +1.5%, EPE +0.9%, WLL +0.9%, RDS.A +0.7%, TOT +0.7%, PBR+0.7%

Other news: NAVB +79.5% (enters into letter of intent with Cardinal Health (CAH) for the Sale of Lymphoseek in North America), CLCD +78.8% (announces its Phase 3 pivotal study evaluating lasmiditan, the SAMURAI study, achieved both the primary and key secondary efficacy endpoints), CPHD +52.1% (to be acquired by Danaher (DHR) for $53.00/share in cash for ~$4 bln enterprise value), NAV +30.5% (Navistar and Volkswagen Truck & Bus to pursue strategic technology collaboration and establish procurement JV with Volkswagen Truck & Bus taking a 16.6% ($256 mln) stake in Navistar at a 25% premium), DVAX+16.4% (provides regulatory update on HEPLISAV-B; FDA will review the overall immunogenicity data from HBV-23 ), THLD+9.1% (may be in sympathy with other biotech peers), SE +8.7% (Spectra Energy and Enbridge (ENB) to combine in a stock-for-stock merger transaction which values Spectra Energy common stock at $40.33 per share), ESI +6.7% (will discontinue academic operations at all of its ITT Technical Institutes permanently due to actions of and sanctions from the U.S. Department of Education), SSYS +5.2% (General Electric (GE) said it plans to pay $1.4 bln to acquire 3D printing companies Arcam AB and SLM Solutions Group AG), DDD +4.8% (General Electric (GE) said it plans to pay $1.4 bln to acquire 3D printing companies Arcam AB and SLM Solutions Group AG), SGMO +4.2% (granted orphan designation by the FDA for its Adeno-associated virus serotype 2/6 vectors encoding zinc finger nucleases and human factor 9 gene for the treatment of hemophilia B), SGMO +4.2% ( confirms orphan designation for its Adeno-associated virus serotype 2/6 vectors encoding zinc finger nucleases and human factor 9 gene for the treatment of hemophilia B), VJET +4.1% (General Electric (GE) said it plans to pay $1.4 bln to acquire 3D printing companies Arcam AB and SLM Solutions Group AG), TTM +4.1% (Sensex up 1.5% overnight), TEF +2.7% (announces intent to proceed of IPO of its subsidiary of Telxius Telecom), IBN +2.4% (Sensex up 1.5% overnight), PNNT +1.9% (announced quarterly distribution of $0.28 per share (unchanged from prior)), RADA +1.9% (ecieves follow-on orders, for delivery of ground debriefing stations, totaling $2 mln; deliveries are to be completed by mid-2017), BABA +1.4% (launches Canadian Pavilion on Tmall Global; Air Canada and Alitrip sign deal), HLF +1% (Joint/Group Filing including Carl Icahn disclosed the purchase of nearly 307K shares, worth total of $18.5 mln (transaction date 8/31)), .

Analyst comments: FNSR +4.8% (upgraded to Buy at Stifel), HL +3.6% (initiated with a Buy at Rodman & Renshaw; tgt $9),GT +2.9% (upgraded to Buy from Hold at Deutsche Bank), SAN +1.5% (upgraded to Overweight at Barclays), WPZ +1.4% (initiates an adviser-led process to explore the monetization of its indirect ownership interest in the Geismar, Louisiana olefins plant and complex), GILD +1.3% (upgraded to Buy at Jefferies), FIVE +1.2% (assumed coverage / upgraded to Neutral from Sell at Goldman), INTC +1% (upgraded to Buy at Evercore ISI), CCI +0.9% (upgraded to Outperform at Oppenheimer)

>>> Danaher to buy Cepheid for USD 53 per share, EV of USD 4bn

Danaher to buy Cepheid for USD 53 per share, EV of USD 4bn

Cepheid (NASDAQ: CPHD) today announced that it has entered into a definitive agreement with Danaher Corporation (NYSE: DHR) under which Danaher will acquire all of the outstanding shares of Cepheid common stock for USD 53 per share in cash, or a total enterprise value of approximately USD 4bn including indebtedness and net of acquired cash.

"Cepheid's vision has always been to enable as many people as possible to have access to powerful molecular diagnostic tests that provide critical information on a timely basis to guide treatment and patient management," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "As a standalone company for the last 20 years, Cepheid has been a leading innovator in molecular diagnostics, to date installing more than 11,000 GeneXpert Systems, and delivering tens of millions of tests spanning healthcare associated infections, critical infectious disease, sexual health, and virology."

"Looking forward as a part of Danaher and its USD 5bn Diagnostics platform, we believe that Cepheid will be able to reach an extended level of customers and patients more quickly than we could have on a standalone basis," continued Bishop. "Our employees will have more opportunities as part of a global science and technology company that shares Cepheid's commitment to innovation, and also has the capability to help accelerate expansion of our global market position."

The consideration represents approximately a 54% percent premium to Cepheid's common stock over the closing price of USD 34.42 on September 2, 2016. Cepheid's Board of Directors unanimously approved the transaction, which is expected to close in the fourth quarter of 2016, subject to Cepheid shareholder approval, clearances by the relevant regulatory authorities and other customary closing conditions.

Fenwick & West LLP is acting as Cepheid's legal advisor for this transaction, and Goldman, Sachs & Co. is acting as Cepheid's exclusive financial advisor.

>>> Morgan Stanley Throws In The Bearish Towel, Sees S&P At 2,300 On A 19x "Bull

Morgan Stanley Throws In The Bearish Towel, Sees S&P At 2,300 On A 19x "Bull Case" PE Multiple

When Morgan Stanley's Adam Parker had a notable change in heart earlier in the year when he turned from a raging bull to a muted bear, it unleashed a series of odd letters to MS clients such as this one from April where "In Bizarre, Schizophrenic Note Morgan Stanley Compares Rally Chasers To "Cockroaches", followed by an angry noted aimed at "Fake Contrarians Who "Only Care About Price", culminating with a letter in July in which he feared becoming the "counter-indicating idiot."
Well, several months later, with the central banks refusing to allow his bearish narrative to manifest itself, this morning Parker flip-flopped again, and once more threw in the towel, this time reverting back to his old bullish ways, when overnight he released a note titled that "We Think the US Stock Market Is Going Higher", something he didn't think for most of 2016.
The justification of his racent change of heart was the same one used by so many other analysts who have zero fundamental legs to stand on: the Fed Model, or low bond yields resulting in high equity valuations. This is what he said:


We are raising our 12-month price targets for the S&P 500 – base case from 2200 to 2300, bear case from 1600 to 1800, and our bull case from 2400 to 2500. Our bull-bear skew is balanced, and our base case upside is now mid-single-digit, consistent with our continued optimistic outlook. While we have argued many times that we think forecasting the market-level price-to-earnings ratio is difficult, our best guess is that growth and interest rates ultimately matter in the long term. In fact, we have shown that historically, there was a relationship between real yields and price-to-earnings ratios for the markets Exhibit 1).
Parker summarizes his cognitive dissonance as follows:



In the past, extreme real yields, like where we are now at near 0%, were associated with lower price-to-earnings multiples because typically these were perceived as riskier regimes where the world was reliant on policymakers and their efficacy. So perhaps, the bubble we are all searching for is simply in the belief in the policymakers. On the other hand, a real yield of zero could be 17% on the 10-year yield and 17% on CPI, or 1.5% and 1.5%, and perhaps history isn’t a perfect guide, as different levels create different forward outlooks. Perhaps today's unconventional policy and heightened determination of policymakers mean that not all of history is relevant? Perhaps you can have a low-risk, extreme real yield environment? Admittedly, there is limited evidence of a low-risk, extreme real yield regime in the past, but, over the past few quarters we have been arguing that perhaps this historical relationship was broken this cycle
That said, Parker is now optimistic on the S&P for 4 main reasons:
  1. Bond yields are so low and seem risky – the old "relative to other asset classes" argument.
  2. 70% of the global equities that trade $100 million or more each day are in the US – the old liquidity argument.
  3. The US is the only major region with potentially positive EPS growth as a base case – the old fundamental argument.
  4. Investors aren’t positioned for big upside- whether you look at futures, options, prime brokerage data, surveys, or anecdotally from meetings, we don’t see excessive optimism among the client base – i.e., the old positioning argument.
What is amusing is that Parker still refuses to full let go of the bearish thesis, saying that "on classic metrics like price-forward earnings, the market is clearly more expensive than its historical median (Exhibit 2)."

However, in a nod to the momentum chasers he was mocking less than 6 months ago, Parker concedes that "this may not be an impediment. The US equity market offers a 2% dividend yield and more than a 2% net buyback, with we think about 3.5% per annum EPS growth for the next two years (Exhibit 3).

So how does Parker get to a 2,300 "base case" target as shown above: simple - not by raising earnings forecasts, which are set to decline for a 6th consecutive quarter, but by, drumroll, raising PE multiple expectations, which rise from a goalseeked 17.0 to 17.7x in the base case, and from 18x to 19x in the bull case forecast, resulting in a 2,500 S&P target.


This call option on EPS growth relative to low expectations today we think offers more attractive risk-reward than most other major asset classes. We left our base case EPS for the S&P500 unchanged, but raised our price-to-earnings assumption from 17x to 17.7x. For our bear case, we raised our EPS assumption from $100 to $106.9 two years out, viewing the flat EPS so far this year as a relative positive, implying that the acute drop-off factored into our prior bear case as increasingly unlikely. We are raising our bear case multiple from 16x to 16.8x. For the bull case, we are leaving our EPS essentially unchanged, moving the out year from $137.1 down to $136.5, but raising our bull case multiple from 18x to 19x, yielding our new 2500 bull case forecast.
The punchline, however, is Parker, "2020" forecast, where he still sees the S&P at 3,000 in just over four years:


The case for 2020: Two years ago, we partnered with our Chief US Economist Ellen Zentner to argue that we think this could be a long expansion, perhaps lasting until 2020, and implying that the US equity market will trade near 3000 by cycle end. We still believe this to be true, as most US consumer metrics appear directionally positive (housing, jobs, delinquencies, obligations, confidence, personal spending, etc.); corporate excess seems under control; and low growth is still the base case economic forecast. With few other attractive investment alternatives, we see the US equity market as the beneficiary of further appreciation.
We wonder if in a few months Parker will be raging at himself as the "fake contrarian" whose call led to the next move lower in stocks a la Gartman and Goldman, and dragging MS clients into the market back at its all time, or if this is that rare for 2016 case where a sellside strategist is actually correct.

>>> US Early premarket gappers

Early premarket gappers
Gapping up: CPHD +52.6%, NAV +26%, DVAX +16.4%, THLD +9.9%, VJET +7.7%,EPE +5.6%, DDD +5.5%, SSYS +5.1%, TTM +4.5%, WLL +4.2%, AUY +3.9%, AUY+3.9%, AG +3.6%, IBN +3.4%, MUX +2.8%, MT +2.6%, FNSR +2.5%, TEF +2.5%,CHK +2.3%, ABX +2.2%, SDRL +1.7%, SLW +1.7%, GDX +1.7%, NEM +1.5%, QGEN+1.5%, GG +1.4%, EXEL +1.4%, MON +1.3%, BHP +1.3%, RDS.A +1.3%, SAN+1.3%, TOT +1.3%, GOLD +1.3%, VRX +1.2%, PBR +1.1%, BBL +1%

Gapping down: VIP -6.9%, HMY -4.2%, LYG -2.4%, SBGL -1.6%, BCS -1.4%, MRVL-1.2%, DEO -1.2%, UN -1.2%, CCL -1%, GSK -1%, DB -0.9%